Enjoying this discussion, agreed agreed. For me the real win in that situation is finding a committed partner in India who will help make sure buc is effectively distributed (when the time comes) to patients/customers there and beyond. We wait, with an increased sense of opportunity.
I think you understand my logic perfectly. While the FDA (powers that "B") look at our data and decide our fate, somebody at Revive has decided we should have a good plan in place outside of the U.S. So tell me, why would somebody at Revive come to the conclusion we need a good plan outside of the FDA jurisdiction?
News 
Market Data 
Discover 
